Agreement will facilitate clinical trial of MedX’s DermSecure® at three university hospitals
MISSISSAUGA, Ontario, November 16, 2021–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) and Makromed/Arhan Global A.Ş (“Makromed/Arhan”) are pleased to announce a Memorandum of Understanding between the companies on a distribution agreement for MedX’s leading-edge DermSecure® Screening Platform, facilitating a clinical trial of the technology at three university hospitals across Turkey in early 2022.
Pending the successful completion of the agreement’s pilot phase, the MedX DermSecure® Screening Platform will become more widely available across the country. The distribution agreement is the latest in a series of European commercialization pilots recently launched as part of MedX’s global commercialization strategy, building on pilots currently underway in the Netherlands and Italy. Additional commercialization pilots are anticipated in the coming months.
“I founded Makromed on the principle of the Hippocratic Oath (“first do no harm”) – for our team, the well-being of our patients is of primary importance,” said Dr. Hasan Silav, Owner and CEO of Makromed/Arhan. “We are confident that bringing MedX’s world-class teledermatology platform to this market will greatly improve outcomes for those dermatology patients seeking high-quality, virtual services. We look forward to working with MedX to increase this platform’s availability to patients across Turkey.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure® Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions; providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
Sylvain Desjeans, MedX CEO said, “We look forward to partnering with Makromed to introduce our platform to the Turkish market. This agreement builds on MedX’s commercial growth in Europe and is key to expanding our footprint around the globe, improving patient outcomes, and potentially saving more lives.”
Naman Demaghlatrous, MedX Managing Director of Europe, Middle East and Africa, added, “With Makromed being one of the largest medical device distributors in the Turkish market, this agreement is a significant opportunity to rapidly grow MedX’s presence, providing greater access to our technology at a time when skin care patients need a virtual service like this the most.”
According to the World Health Organization’s latest data in 2018, there were an estimated 1,201 skin cancer related deaths in Turkey.1 Early and rapid detection of melanoma is key to improving patient outcomes.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
About Makromed/Arhan Global A.Ş:
Makromed, headquartered in Izmir, Turkey, was founded in 2002 with a mission to provide caregivers and patients across Turkey with state-of-the-art products for better outcomes and to improve patients’ quality of life. Makromed has since been the distributor of many reputable multinational suppliers such as Evrenler, J&J, Smith & Nephew, Stryker, BBraun, Covidien and Medtronic. Under Arhan Global A.Ş, Makromed extended its services to manufacturing healthcare and patients’ protection and safety garments that are high quality CE and ISO certified. Visit https://www.makromed.com.tr/.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
1 Source: https://www.worldlifeexpectancy.com/turkey-skin-cancers
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116006363/en/
Bill Mitoulas, Investor Relations
MedX Health Corp.
Dr. Hasan Silav
Makromed/Arhan Global A.Ş